Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver

Virus Research

Volumn 148, Issue 1-2, 2010, Pages 51-59

  Koeberlein, Bernd ^a   Hausen, Axel zur ^b   Bektas, Nuran ^c   Zentgraf, Hanswalter ^d   Chin, Ruth ^e   Toan, Nguyen Linh ^a,f   Kandolf, Reinhard ^a   Torresi, Joseph ^e   Bock, C Thomas ^a,g  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f VIETNAM MILITARY MEDICAL UNIVERSITY   (Viet Nam)

^g ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Adenovirus; Cellular signaling; Chronic hepatitis B; Hepatocellular carcinoma; Immunohistochemistry; Inflammation

Indexed keywords

INTERLEUKIN 10 RECEPTOR ALPHA; JANUS KINASE; STAT PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADENOVIRUS; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL INTERACTION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC REGULATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; VIRUS INDUCTION;

ADOLESCENT; ADULT; AGED; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; YOUNG ADULT;

ADENOVIRIDAE; HEPATITIS B VIRUS;

EID: 75149188195     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.12.003     Document Type: Article

References (46)

1. Bock C.T., Malek N.P., Tillmann H.L., Manns M.P., and Trautwein C. The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro. J. Virol. 74 5 (2000) 2193-2202
2. Bock C.T., Tillmann H.L., Maschek H.J., Manns M.P., and Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 113 6 (1997) 1976-1982
3. Bock C.T., Toan N.L., Koeberlein B., Song le H., Chin R., Zentgraf H., Kandolf R., and Torresi J. Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of STAT/SOCS signaling in hepatocellular carcinoma. Intervirology 51 6 (2008) 432-443
4. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., and Haussinger D. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17 3 (2003) 488-490
5. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. STAT3 as an oncogene. Cell 98 3 (1999) 295-303
6. Chin R., Earnest-Silveira L., Koeberlein B., Franz S., Zentgraf H., Bowden S., Bock C.T., and Torresi J. Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins. Antivir. Ther. 13 2 (2008) 221-230
7. Chin R., Earnest-Silveira L., Koeberlein B., Franz S., Zentgraf H., Dong X., Gowans E., Bock C.T., and Torresi J. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J. Hepatol. 47 3 (2007) 325-337
8. Christen V., Duong F., Bernsmeier C., Sun D., Nassal M., and Heim M.H. Inhibition of alpha interferon signaling by hepatitis B virus. J. Virol. 81 1 (2007) 159-165
9. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., and Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 6 (1994) 1513-1520
10. Dostert C., Jouanguy E., Irving P., Troxler L., Galiana-Arnoux D., Hetru C., Hoffmann J.A., and Imler J.L. The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of drosophila. Nat. Immunol. 6 9 (2005) 946-953
11. Dries V., von Both I., Muller M., Gerken G., Schirmacher P., Odenthal M., Bartenschlager R., Drebber U., Meyer zum Buschenfeld K.H., and Dienes H.P. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology 29 1 (1999) 223-229
12. Duechting A., Tschope C., Kaiser H., Lamkemeyer T., Tanaka N., Aberle S., Lang F., Torresi J., Kandolf R., and Bock C.T. Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J. Virol. 82 16 (2008) 7942-7952
13. Durbin J.E., Hackenmiller R., Simon M.C., and Levy D.E. Targeted disruption of the mouse STAT1 gene results in compromised innate immunity to viral disease. Cell 84 3 (1996) 443-450
14. Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., Nakajima K., and Hirano T. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5 5 (1996) 449-460
15. Hyodo N., Tajimi M., Ugajin T., Nakamura I., and Imawari M. Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. Hepatol. Res. 27 2 (2003) 109-116
16. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95 13 (1998) 7556-7561
17. Kim K.A., Lin W., Tai A.W., Shao R.X., Weinberg E., De Sa Borges C.B., Bhan A.K., Zheng H., Kamegaya Y., and Chung R.T. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J. Hepatol. 50 4 (2009) 705-711
18. Klein C., Bock C.T., Wedemeyer H., Wustefeld T., Locarnini S., Dienes H.P., Kubicka S., Manns M.P., and Trautwein C. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125 1 (2003) 9-18
19. Klein N.P., and Schneider R.J. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell Biol. 17 11 (1997) 6427-6436
20. Krebs D.L., and Hilton D.J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19 5 (2001) 378-387
21. Lan K.H., Lan K.L., Lee W.P., Sheu M.L., Chen M.Y., Lee Y.L., Yen S.H., Chang F.Y., and Lee S.D. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J. Hepatol. 46 5 (2007) 759-767
22. Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V., and Chung R.T. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 128 4 (2005) 1034-1041
23. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 49 Suppl. 5 (2009) S45-S55
24. Miller D.M., Zhang Y., Rahill B.M., Waldman W.J., and Sedmak D.D. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol. 162 10 (1999) 6107-6113
25. Moutsopoulos N.M., Vazquez N., Greenwell-Wild T., Ecevit I., Horn J., Orenstein J., and Wahl S.M. Regulation of the tonsil cytokine milieu favors HIV susceptibility. J. Leukoc. Biol. 80 5 (2006) 1145-1155
26. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat. Rev. Immunol. 5 5 (2005) 375-386
27. Ramana C.V., Kumar A., and Enelow R. STAT1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of STAT3 in mouse embryonic fibroblasts. Biochem. Biophys. Res. Commun. 327 3 (2005) 727-733
28. Rehermann B., Lau D., Hoofnagle J.H., and Chisari F.V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97 7 (1996) 1655-1665
29. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 3 (2005) 215-229
30. Robek M.D., Boyd B.S., Wieland S.F., and Chisari F.V. Signal transduction pathways that inhibit hepatitis B virus replication. Proc. Natl. Acad. Sci. U.S.A. 101 6 (2004) 1743-1747
31. Shen X., Hong F., Nguyen V.A., and Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 480 2-3 (2000) 132-136
32. Shi Y.H., and Shi C.H. Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol. 15 25 (2009) 3099-3105
33. Stoiber D., Kovarik P., Cohney S., Johnston J.A., Steinlein P., and Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J. Immunol. 163 5 (1999) 2640-2647
34. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., Kubo M., Yamashita A., Okabe M., Takeda K., Akira S., Matsumoto S., Toyonaga A., Sata M., and Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med. 193 4 (2001) 471-481
35. Tannapfel A., Anhalt K., Hausermann P., Sommerer F., Benicke M., Uhlmann D., Witzigmann H., Hauss J., and Wittekind C. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J. Pathol. 201 2 (2003) 238-249
36. Tschope C., Bock C.T., Kasner M., Noutsias M., Westermann D., Schwimmbeck P.L., Pauschinger M., Poller W.C., Kuhl U., Kandolf R., and Schultheiss H.P. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 111 7 (2005) 879-886
37. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., and Jove R. STAT3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol. 18 5 (1998) 2545-2552
38. Waris G., Huh K.W., and Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT3 and NF-kappa B via oxidative stress. Mol. Cell Biol. 21 22 (2001) 7721-7730
39. Wen Z., and Darnell Jr. J.E. Mapping of STAT3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of STAT1 and STAT3. Nucleic Acids Res. 25 11 (1997) 2062-2067
40. Wu M., Xu Y., Lin S., Zhang X., Xiang L., and Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of STAT1. J. Gen. Virol. 88 Pt. 12 (2007) 3260-3269
41. Xia Y., Roman L.J., Masters B.S., and Zweier J.L. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273 35 (1998) 22635-22639
42. Yang W.J., Chang C.J., Yeh S.H., Lin W.H., Wang S.H., Tsai T.F., Chen D.S., and Chen P.J. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology 49 5 (2009) 1515-1524
43. 705) expression is associated with histological grading and intratumor microvessel density in hepatocellular carcinoma. J. Clin. Pathol. 60 6 (2007) 642-648
44. Yokota S., Yokosawa N., Okabayashi T., Suzutani T., Miura S., Jimbow K., and Fujii N. Induction of suppressor of cytokine signaling-3 by herpes simplex virus type 1 contributes to inhibition of the interferon signaling pathway. J. Virol. 78 12 (2004) 6282-6286
45. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., and Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28 1 (2001) 29-35
46. Zhao L., Hart S., Cheng J., Melenhorst J.J., Bierie B., Ernst M., Stewart C., Schaper F., Heinrich P.C., Ullrich A., Robinson G.W., and Hennighausen L. Mammary gland remodeling depends on gp130 signaling through STAT3 and MAPK. J. Biol. Chem. 279 42 (2004) 44093-44100